Fig. 1 · Structure

Documents & Downloads

GSK1059865

Cat. No. A12401 CAS 1191044-58-2

orexin 1 receptor antagonist

GSK1059865 is a potent orexin 1 receptor antagonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

GSK1059865 Research Summary

This section summarizes 4 in vivo studies of GSK1059865 from 3 published references. In vivo models include male Sprague Dawley rats.

GSK1059865 In Vivo Studies

In male Sprague Dawley rats, GSK1059865 at 5 mg/kg i.p. did not significantly alter recorded sleep parameters compared with vehicle. In male Sprague–Dawley rats, subcutaneous GSK1059865 at 10 mg/kg with vehicle produced a lower NREM bout number than vehicle with vehicle. In male wild-type mice, GSK1059865 significantly attenuated MK-801-elicited cortical glutamate release compared with vehicle-treated mice. In male Sprague-Dawley rats, GSK1059865 significantly decreased expression of the cocaine CPP response compared with Vehicle-Cocaine + Vehicle on test day. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

total sleep time (TST) in Male Sprague Dawley rats (275–300 g, Charles River Italy)

Animal study · Male Sprague Dawley rats (275–300 g, Charles River Italy) [1]

Model: Male Sprague Dawley rats (275–300 g, Charles River Italy). Treatment: 5 mg/kg i.p.. Result: At a lower dose (5 mg/kg i.p.) the compound did not significantly alter any of the sleep parameters recorded.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total sleep time (TST)Reported result At a lower dose (5 mg/kg i.p.) the compound did not significantly alter any of the sleep parameters recorded[1]

Conditions shared by the study groups

Route
i.p.
Treatment course
six hours into the dark phase (Circadian time (CT) 18); 5-hour test period
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK1059865 5 mg/kg i.p.vehicleAt a lower dose (5 mg/kg i.p.) the compound did not significantly alter any of the sleep parameters recorded[1]
GSK1059865 5 mg/kg i.p.
Model: Male Sprague Dawley rats (275–300 g, Charles River Italy)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: GSK1059865

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > OX2R but not OX1R antagonism produces robust sleep-promoting effects (S33); Methods > Sleep recording and analysis (S113, S124, S126, S128); Figure 6 legend (S168)

total sleep time (TST): total sleep time (TST); comparator: vehicle — Results > OX2R but not OX1R antagonism produces robust sleep-promoting effects (S33); Methods > Sleep recording and analysis (S124)

GSK1059865 5 mg/kg i.p. · Results > OX2R but not OX1R antagonism produces robust sleep-promoting effects (S33); Methods > Sleep recording and analysis (S126, S128)

NREM bout number in male rats

Animal study · male Sprague–Dawley rats; n = 7 animals [2]

NREM bout number, 6-h period following the treatment: GSK-1059865 (10 mg/kg) + Vehicle, 70.7±3.7; Vehicle + Vehicle, 82.7±2.6 (*P < 0.05 vs. Vehicle + Vehicle).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NREM bout numberNREM bout number 10 mg/kg, 6-h period following the treatment, GSK-1059865 + Vehicle: 70.7±3.7[2]

Conditions shared by the study groups

Route
subcutaneous (sc) route
Treatment course
at the onset of the dark phase; 6-h period following the treatment
Vehicle
5% pharmasolve, 20% solutol, 75% hydroxypropyl-β-cyclodextrin (20% w/v)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK1059865 10 mg/kgVehicle + VehicleGSK-1059865 (10 mg/kg), 6-h period following the treatment: NREM bout number, GSK-1059865 + Vehicle: 70.7±3.7; Vehicle + Vehicle: 82.7±2.6; *P < 0.05 vs. Vehicle + Vehicle.[2]
GSK1059865 10 mg/kg
Model: male Sprague–Dawley rats; n = 7 animals
Methods and source locations

Compound reported in the paper: GSK1059865

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Drugs and experimental design (S13, S14); Results > Disinhibition of REM sleep by additional pharmacological blockade of OX1R to OX2R antagonism (S45); Table 2 legend (S70, S71); Table 2 (T2.h1, T2.r1, T2.r2)

NREM bout number: NREM bout number; comparator: Vehicle + Vehicle — Table 2 legend (S70, S71); Table 2 (T2.h1, T2.r1, T2.r2)

GSK1059865 10 mg/kg · Materials and methods > Drugs and experimental design (S13); Results > Disinhibition of REM sleep by additional pharmacological blockade of OX1R to OX2R antagonism (S45); Table 2 legend (S70, S71); Table 2 (T2.h1, T2.r1, T2.r2)

Cortical glutamate release in wild-type mice

Animal study · Male wild-type mice [3]

Model: Male wild-type mice. Treatment: 10 mg/kg. Result: In wild-type mice, GSK-1059865 (10 mg/kg, S.C.) significantly attenuated cortical glutamate release elicited by MK-801 (0.178 mg/kg S.C.) (Figure 1A, treatment group: F = 5.537, df = 1, p = 0.037; block: F = 3.677, df = 2, p = 0.057)..

Measured endpoints — not treatment concentrations
EndpointReported resultReference
area under the curve of the baseline change in glutamate release over 1 h post MK-801 stimulationReported result In wild-type mice, GSK-1059865 (10 mg/kg, S.C.) significantly attenuated cortical glutamate release elicited by MK-801 (0.178 mg/kg S.C.) (Figure 1A, treatment group: F = 5.537, df = 1, p = 0.037; block: F = 3.677, df = 2, p = 0.057).[3]

Conditions shared by the study groups

Route
S.C.
Treatment course
30 min prior to the injection of MK-801
Vehicle
30% sulfobutylether(7)-β-cyclodextrin (SBE) or 5% Pharmasolve, 20% Cremaphor and 75% D5W
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK1059865 10 mg/kgvehicle treated miceIn wild-type mice, GSK-1059865 (10 mg/kg, S.C.) significantly attenuated cortical glutamate release elicited by MK-801 (0.178 mg/kg S.C.) (Figure 1A, treatment group: F = 5.537, df = 1, p = 0.037; block: F = 3.677, df = 2, p = 0.057).[3]
GSK1059865 10 mg/kg
Model: Male wild-type mice
Methods and source locations

Compound reported in the paper: GSK1059865

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods (S2, S4, S5, S20, S23, S28, S29); Results (S40)

area under the curve of the baseline change in glutamate release over 1 h post MK-801 stimulation: area under the curve of the baseline change in glutamate release over 1 h post MK-801 stimulation; comparator: vehicle treated mice — Methods (S28); Results (S40)

GSK1059865 10 mg/kg · Methods (S20); Results (S40)

raw time spent in each chamber in Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each

Animal study · Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each [1]

Model: Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each. Treatment: 10 or 30 mg/kg i.p. Result: significantly decreased the expression of the CPP response to cocaine compared to vehicle at 10 mg/kg and 30 mg/kg i.p. (** p<0.01 vs. Vehicle; ANOVA and Student-Newman-Keuls test).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
raw time spent in each chamberReported result significantly decreased the expression of the CPP response to cocaine compared to vehicle at 10 mg/kg and 30 mg/kg i.p. (** p<0.01 vs. Vehicle; ANOVA and Student-Newman-Keuls test)[1]

Conditions shared by the study groups

Route
i.p.
Treatment course
30 minutes prior to the behavioural test
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK1059865 10 or 30 mg/kg i.pVehicle-Cocaine + Vehicle on test daysignificantly decreased the expression of the CPP response to cocaine compared to vehicle at 10 mg/kg and 30 mg/kg i.p. (** p<0.01 vs. Vehicle; ANOVA and Student-Newman-Keuls test)[1]
GSK1059865 10 or 30 mg/kg i.p
Model: Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: GSK1059865

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Pharmacokinetics and bioanalysis (S53); Methods > Sleep recording and analysis (S126); Methods > Conditioned place –preference (CPP) (S131, S141, S142, S144, S149, S150, S151, S152); Figure 7 legend (S174, S176)

raw time spent in each chamber: raw time spent in each chamber; comparator: Vehicle-Cocaine + Vehicle on test day — Methods > Conditioned place –preference (CPP) (S152); Figure 7 legend (S174)

GSK1059865 10 or 30 mg/kg i.p · Methods > Conditioned place –preference (CPP) (S144); Figure 7 legend (S174)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 1191044-58-2
Applications orexin 1 receptor antagonist
Formula C20H23BrFN3O2
Molecular Weight 436.32
SMILES
O=C(N1[C@H](CNC2=NC=C(Br)C=C2)CC[C@H](C)C1)C3=CC=CC(F)=C3OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GSK1059865 Research References

  1. [1] Gozzi A, Turrini G, Piccoli L, et al. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One (2011). PMID: 21307957 DOI: 10.1371/journal.pone.0016406 Source material
  2. [2] Dugovic C, Shelton JE, Yun S, et al. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci (2014). PMID: 24592208 DOI: 10.3389/fnins.2014.00028 Source material
  3. [3] Aluisio L, Fraser I, Berdyyeva T, et al. Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex. Front Neurosci (2014). PMID: 24904253 DOI: 10.3389/fnins.2014.00107 Source material

Added to your cart

View Cart Checkout
Loading...